Checkpoint Inhibitors and Diabetes
PD-L1 and checkpoint inhibitors have been front and center in the media relating to the treatment of cancer. Researches are now...
Dr. Lisa Haile concentrates on patent protection.
Dr. Haile has special technical experience in molecular biology, immunology, cell biology, regenerative medicine including ESCs, iPSCs, pSCs, diagnostics, therapeutics, theranostics, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management.
Dr. Haile is a member of DLA Piper's Executive Committee.
PD-L1 and checkpoint inhibitors have been front and center in the media relating to the treatment of cancer. Researches are now...
Researchers from Harvard identified a new protein, Nrf1, which regulates high cholesterol by binding directly to it. This binding prompts...
We have been hearing for a decade about the use of stem cells to create organs and treat diseases. Today, a study showing that hES...
Roche's Alecensa, a drug for treatment of ALK positive lung cancer, has received a nod from the FDA. While only 5% of lung cancer...
Sanofi has paid big bucks to enter the race to develop a new drug for MS. The drug was developed by Principia Biopharma and crosses the...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net